Immunocore Holdings plc

and welcome to the Immunocore conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation, and you may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Clayton Robertson, Investor Relations. Please go ahead, sir.

Good morning and good afternoon. Thank you for joining us on our Q2 and first half 2025 earnings call. During today's call, we will make some forwarding statements, which are qualified by our state proper provision under the Private Securities Litigation Reform Act of 1995. Please note that actual results can vary materially from those indicated by these forwarding statements, including those discussed in our filings with the SEC. On today's call, I'm joined by Bahidja Jalal, CEO of Immunocore. Ralph Torbay, head of commercial, will review our ChemTrack sales for the second quarter and first half of 2025 and discuss our lifecycle management plans for ChemTrack. David Berman, our head of R&D, will provide key updates from our three phase three clinical trials. Travis Coy, our CFO and head of corporate development, will also provide some key highlights from our financial results reported earlier this morning.

Thank you, Clay. Good morning and good afternoon, everyone. Thank you for joining the call today. We are pleased to report that 2025 is off to a strong start reflected in our robust half-year financial results and the progress of our diversified pipeline as we continue to deliver on our mission. Our strategy is anchored on three core pillars. maximizing the value of ChemTrack, advancing the clinical portfolio, and innovating for sustainable growth. For the first half of 2025, we generated $192 million in ChemTrack revenue, representing 32% growth year over year, an impressive milestone four years post-launch. These results underscore the real-world impact of our therapies and the trust that patients, healthcare professionals, and partners place in our science. Expanding global access to ChemTrack remains our top priority. At the same time, we are executing with discipline and urgency across three Phase III melanoma trials, spanning adjuvants, first-line, and late-stage setting. Beyond ChemTrack, we are progressing multiple early stage programs in oncology and infectious diseases. We remain on track to file the CTA for our autoimmune candidates in type 1 diabetes by year end 2025 and anticipate starting the phase 1 trial in 2026. We also expect the CTA for our second autoimmune program next year. Our pipeline is built on rigorous transformational science, always focused on addressing significant and mathematical needs. We recognize the urgency for patients and are committed to advancing our programs thoughtfully and efficiently. Finally, our strong balance sheet enables us to invest in innovating while maintaining financial discipline. This approach ensures we are well-positioned to deliver long-term value for our shareholders. So now the team will walk you through the details of the quarter, and I'll turn over to Rav.